Pfizer's defining moves.
The defining strategic moves at Pfizer — each one explained and grounded in the record.
The Bet · Decision Forks
Pfizer Didn't Bet the Company on COVID. The Government Covered the Downside.
Pfizer is celebrated for taking $2 billion of pure private risk and turning it into a $100 billion year. But it locked in $5.97 billion of guaranteed orders before a single dose shipped — and then watched the windfall fall 42% in twelve months.
8 min
The Adjacency Expansion · Growth & Expansion
Pfizer Made $57 Billion From COVID. Then It Spent $43 Billion to Replace Itself.
In 2022 COVID products were 57% of Pfizer's revenue. By 2023 they had collapsed 78%, total sales fell 42%, and EPS dropped 93% to $0.37. The acquisition spree that followed wasn't strategy. It was a company outrunning its own cliff.
8 min
The Adjacency Expansion · Adjacency Expansion
Pfizer Spent Two Decades Buying Its Way Out of Its Core. Then It Bought Its Way Back.
Pfizer's animal health, consumer health, and generics arms were sold as diversification. They came attached to pharma megadeals as cargo — and by 2020 Pfizer had spun off all of it to become, by its own 10-K's words, 'a more focused' drugmaker again.
8 min
The Cannibalization Choice · Decision Forks
Pfizer Didn't Get Smaller by Accident. It Was Strip-Mining for a Higher Multiple.
Over a decade Pfizer shed Zoetis, its consumer business, and finally Upjohn — $2.2B raised here, an $8.1B gain there. The story was 'focus on innovation.' The real driver was the EPS math, and a tax-free escape from a declining asset it could not sell clean.
8 min